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Prophylactic vaccineThe N-terminal region of the human papillomavirus (HPV) L2 protein has been shown to contain immune
epitopes able to induce the production of neutralizing and cross-neutralizing antibodies (Gambhira et al.,
2007; Kawana et al., 1999). Using bacterial thioredoxin as a scaffold, we managed to enhance the
immunogenicity of putative L2 neutralizing epitopes, but only a minor fraction of the resulting immune
responses was found to be neutralizing (Rubio et al., 2009). To determine the recognition patterns for non-
neutralizing, neutralizing and cross-neutralizing antibodies, we isolated and characterized a panel of 46
monoclonal antibodies directed against different HPV16 L2 epitopes. Four of such antibodies proved to be
neutralizing, and two of them, both targeting the amino acid (aa) 20–38 region of L2, were found to cross-
neutralize a broad range of papillomaviruses. The epitopes recognized by neutralizing and cross-neutralizing
antibodies were mapped at high resolution and were found to be characterized by distinct recognition
patterns. Even in the case of the L2 20–38 epitope, cross-neutralization of HPV31 pseudovirions proved to be
extremely inefﬁcient, and this was found to be primarily due to the lack of a proline residue at position 30.
HPV16 speciﬁc amino acids in this region also appear to be responsible for the lack of cross-neutralizing
activity, thus suggesting a potential immune escape mechanism. For the aa 71–80 region, instead, the data
indicate that restriction of neutralization to HPV16 is due to sequence (or structural) differences laying
outside of the epitope. Besides providing new insights on the molecular bases of L2-mediated immune
reactivity, the present data may pave the way to novel vaccination approaches speciﬁcally evoking cross-
neutralizing antibody responses.uenheimer Feld 242, 69120
.
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Human papillomaviruses are a heterogeneous group of double
stranded DNA viruses, which can be sub-grouped into cutaneous or
mucosal types, depending on their ability to infect the skin or the
mucosa of the genital or the upper-respiratory tracts. The mucosal
HPV types are further subdivided into two groups: (i) low-risk HPVs
(e.g. types 6 and 11) mainly associated with benign genital warts and
(ii) high-risk HPVs (e.g. types 16 and 18) as the etiological agents of
cervical cancer affecting approximately 500,000 women worldwide
(Munoz et al., 2003).
In the last two decades efforts from several independent groups
have led to the development of efﬁcient prophylactic vaccines against
some mucosal HPV types. They rely on the L1 protein in the form ofvirus-like particles (VLPs) and are either bivalent vaccines containing
HPV16 and HPV18 VLPs (Cervarix™) (Harper et al., 2006; Paavonen
et al., 2007), or tetravalent vaccines also including VLPs from the low-
risk HPV types 6 and 11 (Gardasil™) (Ault, 2007a; Garland et al.,
2007). Both vaccines induce high titers of HPV type-restricted
neutralizing antibodies. Protection against non-vaccine HPV types
(i.e. cross-protection) was observed against closely related HPV types
only (Ault, 2007b), although a broader range of protection has been
reported recently for the Cervarix vaccine (Paavonen et al., 2009).
Previous studies have shown that immunogens derived from the
N-terminal portion (aa 1–120) of the minor capsid protein L2 can
induce the generation of cross-protective antibodies against a broad
range of papillomavirus infections (Alphs et al., 2008; Gambhira et al.,
2007a; Kawana et al., 2001, 2003; Kondo et al., 2007; Pastrana et al.,
2005; Schellenbacher et al., 2009). The major challenge, however, is
the rather low immunogenicity of L2 and several studies have
speciﬁcally addressed this point lately (Alphs et al., 2008; Jagu et al.,
2009; Kondo et al., 2008; Rubio et al., 2009; Schellenbacher et al.,
349I. Rubio et al. / Virology 409 (2011) 348–3592009). In a previous study, we immunized mice with L2 peptides
comprising the putative neutralizing epitopes aa 20–38, 28–42, 56–
75, 64–81, 96–115 and 108–120 inserted into bacterial thioredoxin as
a macromolecular scaffold (Rubio et al., 2009). Analysis of the
resulting sera evidenced strong anti-L2 antibody responses, yet only
a few of these responses proved to be neutralizing and the
corresponding epitopes were not characterized.
In this study, we isolated a panel of 46 monoclonal antibodies
(mAbs) frommice immunizedwith theaforementionedTrx-L2peptides
and characterized in-depth the targets of non-neutralizing, neutralizing
and cross-neutralizing antibodies within the N-terminus of L2. The data
provide information about the speciﬁc recognition patterns of cross-
neutralizing antibodies and also explain why some HPV16 L2-directed
neutralizing antibodies fail to neutralize other HPV types. Our results
further indicate that L1 apparently has no role in restricting L2-
dependent neutralizing activity to HPV16, but that for some epitopesTable 1
Neutralizing, cross-neutralizing and non-neutralizing anti-HPV 16 L2 antibodies.
Antigen mAb Ig
isotype
Neutralization
capacity
(HPV16)
Cross-
neutralization
capacity
Targeted
peptide
(aa)
GST-
ELISA
IB IF A
Trx-L2
(20–38)
K2L2
(20–38)
IgG1 – – 30–35 + + + T
(6
K4L2
(20–38)
IgG2b + + 21–30 + + +
K6L2
(20–38)
IgG1 – – 30–35 + + +
K7L2
(20–38)
IgG2b – – 27–34
K8L2
(20–38)
IgG2b – – 27–35 + + +
K9L2
(20–38)
IgG1 – – 28–35 + + +
K11L2
(20–38)
IgG2b – – 30–35 + + +
K12L2
(20–38)
IgG2b – – 27–35 + + +
K14L2
(20–38)
IgG2b – – 29–35 + + +
K15L2
(20–38)
IgG1 – – 22–31 + + +
K18L2
(20–38)
IgG1 + + 22–30 + + +
Trx-L2
(28–42)
K1L2
(28–42)
IgG1 – – 30–35 + + + T
(9
K2L2
(28–42)
IgG1 – – 30–35 + + +
K3L2
(28–42)
IgG1 – – 30–35 + + +
K4L2
(28–42)
IgG1 – – 28–35 + + +
K7L2
(28–42)
IgG1 – – 29–35 + + +
K8L2
(28–42)
IgG1 + – 32–39 + + +
Trx-L2
(56–75)
K1L2
(56–75)
IgG1 – – 61–75 + + + T
(1
K2L2
(56–75)
IgG1 – – 61–75 + + +
K4L2
(56–75)
IgG1 – – 61–75 + + +
K5L2
(56–75)
IgG1 – – 61–75 + + +
K6L2
(56–75)
IgG1 – – 61–75 + + +
K7L2
(56–75)
IgG1 – – 61–75 + + +
K9L2
(56–75)
IgG1 – – 61–75 + + +
K11L2
(56–75)
IgG1 – – 61–75 + + +
For each monoclonal antibody, the isotype, neutralization capacity (+/−), and the GST-ELI
name of the starting Trx-L2 antigens and the targeted L2 peptide are reported.this restriction is due to single amino acid differences lying eitherwithin
or outside the L2 epitopes of different HPV types. This study thus
provides important insights on the molecular bases of (and require-
ments for) L2-mediated cross-protective immunity and might have an
important impact on the development of novel anti-HPV vaccines.
Results
Characterization of monoclonal antibodies directed against different
epitopes within the N-terminal region of L2
Previous studies have shown that the aa 1–120 region of the L2
protein (here referred to as the ‘L2 N-terminus’) contains potential
targets for both neutralizing and cross-neutralizing antibodies
(Gambhira et al., 2007b; Kondo et al., 2007; Rubio et al., 2009). We
observed, however, that neutralizing titers are generally much lowerntigen mAb Ig
isotype
Neutralization
capacity
(HPV16)
Cross-
neutralization
capacity
Targeted
peptide
(aa)
GST-
ELISA
IB IF
rx-L2
4–81)
K1L2
(64–81)
IgG1 + – 73–79 + + +
K2L2
(64–81)
IgG1/
IgG2b
– – 73–80 + + +
K3L2
(64–81)
IgG1 – – 73–80 + + +
K4L2
(64–81)
IgG1 – – 65–72 + + +
K5L2
(64–81)
IgG1 – – 65–72 + + +
K6L2
(64–81)
IgG1 – – 65–72 + + +
K7L2
(64–81)
IgG1 – – 65–72 + + +
K8L2
(64–81)
IgG1 – – 65–72 + + +
K9L2
(64–81)
IgG1 – – 65–72 + + +
rxL2
6–115)
K1L2
(96–115)
IgG1 – – 96–103 + + +
K2L2
(96–115)
IgG1 – – 96–111 + + +
K3L2
(96–115)
IgG1 – – 96–107 + + +
K4L2
(96–115)
IgG1 – – 97–111 + + +
K5L2
(96–115)
IgG1 – – 96–107 + + +
rx-L2
–120)
K1L2
(1–120)
IgM – – 85–103 + + +
K2L2
(1–120)
IgG1 – – 105–120
K3L2
(1–120)
IgM – – 105–120 + + +
K4L2
(1–120)
IgM – – 105–120 + + +
K5L2
(1–120)
IgM – – 105–120 + + +
K8L2
(1–120)
IgM – – 105–120 + + +
K9L2
(1–120)
IgM – – 105–120 + + +
SA, immunoblot (IB) and immunoﬂuorescence (IF) reactivities (+/−), along with the
Table 2
Neutralizing activities of monoclonal antibodies K4L220–38, K18L220–38, K15L220–38,
K1L264–81, and K8L228–42.
PSV Associated
disease
Monoclonal antibodies
aa 20–38 aa 28–42 aa 64–81
K4 K18 K15 K8 K1
KD=1.7
10−8
KD=3.3
10−8
KD=8.9
10−7
HPV16 Cervical cancer 3125 625 b5 3125 125
HPV18 Cervical cancer 625 3125 b5 b5 b5
HPV31 Cervical cancer b5 50 b5 b5 b5
HPV45 Cervical cancer 625 625 b5 b5 b5
HPV58 Cervical cancer 625 3125 b5 b5 b5
HPV57 Common warts 625 625 b5 b5 b5
HPV27 Common warts 625 625 b5 b5 b5
BPV-1 Bovine
ﬁbropapilloma
625 125 b5 b5 b5
KD = dissociation constant, units in molar.
The activities of each mAb are expressed as (cross-)neutralization titers, i.e., the
reciprocal of the maximum dilution causing≥70% neutralization of the indicated
pseudovirions (PSV); data are the average of duplicates.
Dissociation constant value for K4 (20–38), K18(20–38) and K15(20–38) obtained by
Biacore analysis are indicated.
350 I. Rubio et al. / Virology 409 (2011) 348–359than ELISA titers, suggesting that most antibodies against the L2 N-
terminus are non-neutralizing. In the present work we set out to
determine the speciﬁc targets recognized by three different types of
antibodies: (i) antibodies that bind to various regions of the HPV16 L2
N-terminus, yet fail to neutralize; (ii) antibodies that bind and
neutralize the parental HPV16 serotype only; and (iii) antibodies
capable of cross-neutralizing different HPV types.
Mice previously immunized with Trx-scaffolded L2 peptides (Rubio
et al., 2009) were used to isolate a panel of 46 monoclonal antibodies2    4   6    7    8    9   11  12  14 15  18 
Antigen aa 20-38
1    2    3    4    7    8
Antigen aa 28-42
1    2   4    5    6 
Antigen aa 56
1-15
5-19
9-23
13-27
17-31
21-35
25-39
29-43
33-47
37-51
41-55
45-59
49-63
53-67
57-71
61-75
65-79
69-83
73-87
77-91
81-95
85-99
89-103
93-107
97-111
101-115
105-119
106-120
Peptides
Fig. 1. Peptide epitopes within the HPV16 L2 N-terminus bound by different monoclonal antib
L2 antigens (listed at the top of each panel), to overlapping 15-mer peptides spanning the aa
with the various mAbs are represented as coloured squares, with black corresponding to th
antibodies are boxed.directed against theL2N-terminal regions comprised of aa 20–38, 28–42,
56–75, 64–81 and96–115 aswell as the entire aa 1–120polypeptide. The
IgG isotypes as well as the neutralization and cross-neutralization
capacities of these mAbs are reported in Table 1. All antibodies were
reactive inGST-L2ELISA andbound to theHPV16L2protein expressedby
transfected 293TT cells in both immunoblot and immunoﬂuorescence
assays, thus indicating that L2 structural changes induced by different
analytical procedures did not affect antigen/antibody recognition.
Only four of the 46 mAbs were capable of neutralizing HPV16
pseudovirions. Two of them were directed against the aa 20–38 region
(K4L220–38 and K18L220–38) and the other two against the aa 28–42
(K8L228–42) and 64–81 (K1L264–81) regions of HPV16 L2 (Table 1). The
ability of these antibodies to cross-neutralize the high-risk types HPV58
31, 45, 18 and BPV type 1 as well as the commonwarts types HPV57 and
27 was determined using the non-neutralizing K15L220–38 mAb (see
later) as a control. As shown in Table 2, only antibodies K4L220–38 and
K18L220–38 were capable of cross-neutralizing PV types other than
HPV16, albeit with somewhat different efﬁciencies. Antibodies
K8L228–42 and K1L264–81 only neutralized homologous HPV16 pseudo-
virions without any effect on other PV types.
Binding patterns of neutralizing, cross-neutralizing and non-neutralizing
antibodies
The aforementioned results indicate that speciﬁc L2 regions,
previously reported as targets for the generation of neutralizing
antibodies (Gambhira et al., 2007b; Kondo et al., 2007), are also
recognized by non-neutralizing antibodies. We thus wished to deﬁne
more precisely the recognition patterns of these different types of
antibodies. To this end, all mAbs were tested in ELISAs using 15-mer
overlapping peptides as targets, which covered the N-terminal 120 aa
of L2 with an offset of 4 aa each, (Fig. 1).   7   9
-75
1    2    3    4    5    6   7    8   9
Antigen aa 64-81
1    2    3    4   5 
Antigen aa 96-115
1    3    4    5   8    9 
Antigen aa 1-120
odies. Binding of different mAbs, isolated frommice immunized with the indicated Trx-
1–120 region of HPV16 L2 was screened by ELISA. The reactivity of individual peptides
e highest reactivity and pale yellow indicating lack of reactivity; the four neutralizing
351I. Rubio et al. / Virology 409 (2011) 348–359We observed that antibodies raised against the same L2 region may
exhibit different recognition patterns, thereby allowing to distinguish
betweenneutralizing and non-neutralizing responses. Brieﬂy, the cross-
neutralizing mAbs K4L220–38 and K18L220–38 recognized a pair of
peptides encompassing aa 17–31 and 21–35, whereas the
corresponding non-neutralizing mAbs reacted with peptides 21–35
and 25–39 (K2L220–38, K6L220–38, K7L220–38, K8L220–38, K11L220–38,
K12L220–38, and K14L220–38) and in one case (K9L220–38) with the
further downstream 29–43 peptide, but not with the 17–31 peptide.
Interestingly, one antibody (K15L220–38) displayed a similar binding
pattern as the two neutralizing antibodies, yet failed to neutralize. As
suggested by the results of comparative surface plasmon resonance
experiments (KD in Table 2), this is likely due to the reduced binding
afﬁnity of this particular antibody (apparent KD=8.9×10−7), which is
50- and 30-fold lower than that of K4L220–38 and K18L220–38,
respectively.
Antibodies directed against the aa 28–42 region also showed
distinct binding patterns. K8L228–42 (HPV16 neutralizing) recognized
the aa 25–39 and 29–43 peptides, whereas the other ﬁve mAbs (non-
neutralizing) additionally reacted with the aa 21–35 peptide (Fig. 1).
These data indicate that the aa 20–42 region of L2 contains epitopes
capable of inducing all three types of antibody responses.
The fourth neutralizing antibody (K1L264–81) is directed against
the aa 64–81 region and recognized peptides spanning aa 65–79, 69–
83 and 73–87. By comparison, the non-neutralizing mAbs K2L264–81
and K3L264–81 only recognized peptides spanning aa 65–79 and 69–
83, whereas the other six non-neutralizing mAbs targeting this region
reacted with peptides 61–75 and 65–79 (Fig. 1). The aa 64–81 region
of L2 thus also contains binding sites for neutralizing and non-
neutralizing antibodies.
The remaining mAbs, directed against regions 56–75, 96–115 and
1–120, were all non-neutralizing (Fig. 1).
The epitopes recognized by the four neutralizing antibodies were
mapped at higher resolution, and compared with those recognized by
some of the non-neutralizing antibodies, by using peptides shortened
stepwise by one amino acid from the N- or the C-terminus, up to a
minimum size of eight amino acids. As shown in Fig. 2A, the
neutralizing mAbs K4L220–38 and K18L220–38 reacted with peptidesNon-neutralizing antibodies
Neutralizing HPV 16
Cross-neutralizing antibodies
K T C K Q A G T C P P D
K14L2(20
K9L2(20-3
K7L2(20-38
K4L2(20-38)
K18L2(20-38)
K15L2(20-38)
K8,K12L2(
K2,K6,K11L
A
B
S G T G G R T G Y I
K4-K9L2(64-81)
20 21 22 23 24 25 26 27 28 29 30 31
64 65 66 67 68 69 70 71 72 73
Fig. 2. Binding patterns of neutralizing, cross-neutralizing and non-neutralizing anti-L2 antib
N- or the C-terminus were used to map the core epitopes recognized by different mAbs inencompassing aa 21–30 and 22–30, respectively, while the
corresponding non-neutralizing mAbs recognized a region of L2
comprised between aa 27 and 35. The neutralizing antibody K8L228–42
recognized the aa 32–39 region, whereas the rest of anti-L2(28–42)
(non-neutralizing) mAbs recognized immune epitopes located be-
tween aa 28 and 35.
For region 64–81, six of the non-neutralizing antibodies recog-
nized an epitope spanning aa 65–71, two non-neutralizing mAbs
(K2L264–81 and K3L264–81) recognized the aa 72–79 peptide, while the
neutralizing K1L264–81 mAb reacted with a one-residue shorter
epitope (aa 72–78) within the same region (Fig. 2B).
Cross-neutralizing antibodies K4L220–38 and K18L220–38 have different
minimal amino acid requirements for target recognition
To identify L2 residues critically involved in binding by the cross-
neutralizing mAbs K4L220–38 and K18L220–38, we performed an
alanine-scanning peptide ELISA. Brieﬂy, replacement of any of the
amino acids between positions 21–23 (TCK) and 28–29 (CP) with an
alanine resulted in a strong reduction of the binding capacity of mAb
K4L220–38 (Fig. 3A). By comparison, loss of K18L220–38 binding was
only observed when either one of the two cysteines at positions 22 and
28 was replaced with an alanine (Fig. 3B). These cysteine residues,
which were also important for K4L220–38 binding, have recently been
shown to exist in an oxidized, disulﬁde-bonded form in infectious HPV
particles (Campos and Ozbun, 2009). As revealed by a comparative
immunoblot analysis (Supplementary Fig. 1) conducted on N97%
oxidized andN75% reduced TrxL2(20–38)3 (see ‘Materials andmethods’
for details), both mAbs preferentially recognized the oxidized (S–S)
form of the antigen (Supplementary Fig. 1).
HPV31 escapes neutralization by mAb K4L220–38 due to a serine/proline
replacement at position 30
HPV31 pseudovirions were the least efﬁciently neutralized by
K18L220–38 and were not at all neutralized by K4L220–38. In the L2
protein, amino acids at positions 20 (Q→K), 24 (A→Q) and 30 (S→P)
differ between HPV31 and HPV16. By reverting the Ser at position 30I I P K V E G K T I A
-38); K7L2(28-42)
8); K4(28-42)
)
K8L2(28-42)
20-38)
2(20-38);  K1- K3L2(28-42)
P L G T R P P T
K1L2(64-81)
K2,K3L2(64-81)
32 33 34 35 36 37 38 39 40 41 42
74 75 76 77 78 79 80 81
odies. Overlapping peptides progressively shortened by one amino acid from either the
the aa 20–42 (A) and the aa 64–81 (B) regions of L2.
1302
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B
Fig. 3. Recognition proﬁles of the cross-neutralizing antibodies K4L220–38 and K18L220–38.
An alanine scanning analysis of the aa 20–31 L2 epitope was performed to determine the
binding patterns of mAbs K4L220–38 (A) and K18L220–38 (B). Amino acid residues that are
required forbindingby the twoantibodies (e.g., theCys residuesatpositions22 and28) are
shown in a dark-grey background.
352 I. Rubio et al. / Virology 409 (2011) 348–359of the HPV31 L2 peptide to a Pro residue (as in HPV16 L2), K4L220–38
binding to HPV31 L2 increased by about three-fold (Fig. 4). An
additional A→Q substitution at position 24 almost completely
restored reactivity with mAb K4L220–38. At variance with the S/P
substitution at position 30, single changes at position 20 or 24 did not
appreciably inﬂuence antibody binding even though a somewhat
increased K4L220–38 binding was observed upon simultaneous
substitution of both residues. In contrast to the stringent sequence
requirements of K4L220–38, the K18L220–38 antibody recognized all
peptides regardless of modiﬁcation (Fig. 4). ELISA data further
corroborated the notion that Pro30 in HPV16 L2 is indeed crucial for
binding by K4L220–38. Thus, the inability of this HPV16 L2 monoclonal31 Q(20)K
31 S(30)P
31 A(24)Q
31 (20+24)
31 (24+30)
31 parental
16 parental
0 25
Q T C K A A G T C P S D
Q T C K Q A G T C P P D
K T C K Q A G T C P S D
Q T C K Q A G T C P S D
Q T C K A A G T C P P D
K T C K A A G T C P S D
K T C K Q A G T C P P D
20 31
Fig. 4. Reactivity of mAbs K4L220–38 and K18L220–38 with hybrid (HPV31/16) aa 20–31 pep
positions of HPV16, along with the unmodiﬁed parental peptides, were used to identify ke
K4L220–38. Antibody reactivity with each L2 aa 20–31 peptide was determined by peptide Eantibody to neutralize HPV31 pseudovirions appears to be due to the
different primary structure of HPV31 L2. Alternatively, it is possible
that this phenomenon may be indirectly caused by the HPV31 L1/L2
interaction, which might negatively inﬂuence immune reactivity by
limiting access of the antibody to L2 or by changing the conformation
of the L2 epitope. To distinguish between these possibilities, we
examined the accessibility of this particular epitope in hybrid particles
containing HPV16L1/31 L2 or HPV31L1/16 L2. We also examined
hybrid particles containing various mutated forms of HPV31 L2,
bearing single, double or triple amino acid substitutions in the aa 20–
31 region, the latter of which fully converts the HPV31 L2 epitope to
the corresponding HPV16 epitope. The results of neutralization assays
carried out with these pseudovirions are shown in Fig. 5. In summary,
both antibodies were able to neutralize infection by the hybrid
particles HPV31L1/16 L2. Consistent with its ability to neutralize
HPV31 pseudovirions, mAb K18L220–38 also neutralized HPV16L1/31
L2 particles, albeit with a lower efﬁciency. In addition, the S30P
substitution in HPV31 L2 restored the neutralizing activity of mAb
K4L220–38 to about 70% of the level observed with HPV31L1/16 L2
hybrid particles. Both mAbs were able to neutralize pseudovirions
bearing an HPV31 L2 with all three amino acids shifted to those of
HPV16 L2, although with a slightly decreased efﬁciency compared to
homologous HPV16 or hybrid HPV31L1/16 L2 pseudovirions.Type-speciﬁcity of the HPV 16 L2(28–42) and (64–81) epitopes
K8L228–42 and K1L264–81 are HPV16 type-restricted, neutralizing
antibodies which bind the aa 32–39 and 72–78 epitopes, respectively.
To ﬁnd out why these antibodies are only able to neutralize HPV16,
critical amino acid residues required for binding of K8L228–42 and
K1L264–81 were determined.
We found that the aa 31–40 HPV16 peptide was bound strongly by
K8L228–42, while the corresponding peptide fromHPV52/58 (HPV types
52 and 58 are identical in this region) was not (Fig. 6A). A V→I
substitution at position 32 of HPV52/58 L2 partially restored K8L228–42
binding, whichwas completely recovered following a T→K substitution
at position 39. The aa 31–40 peptide from HPV18 was not strongly
bound by K8L228–42 either, probably because, similar to HPV52/58, it
also lacks the critical Lys residue at position 39 (as well as an Ile residue
at position 32). HPV18 has one additional change compared toHPV16—
a Val instead of an Ile residue at position 33. When only this valine
residue was replaced with an isoleucine, full binding by K8L228–42 was
recovered. TheHPV45peptidewas themostweakly boundbyK8L228–42.
In addition to the absence of the critical Lys residue at position 39 and Ile
at position 32, it bears an Asn at position 34 compared to a Pro residue in
HPV16. The fact that a single substitution of this Pro residue in HPV16
with an Asn residue as in HPV45 drastically reduced K8L228–42 binding
indicates that this residue is also quite critical for antibody recognition.
Thus Lys39 and Pro34, and to a lesser extent Ile33, appear to be keyK18L220-38
K4L220-38
50 75 100 125
relative binding (%)
tides. HPV31 peptides bearing one or two amino acids derived from the corresponding
y amino acid residues responsible for the lack of HPV31 cross-neutralization by mAb
LISA (see ‘Materials and methods’ for details).
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Fig. 5. Neutralization of hybrid HPV31 L1/L2-HPV16 L1/L2 pseudovirions by mAbs K4L220–38 and K18L220–38. Hybrid particles containing the unmodiﬁed HPV31 L1/HPV16 L2
proteins (and vice versa) as well as hybrid particles containing HPV16 L1 and various HPV16-adapted variants of the aa 20–31 peptide from HPV31 L2 (see also Fig. 4) were used to
analyze the (cross-)neutralization capacity of mAb K4L220–38 (#4); mAb K18L220–38 (#18) served as a reference for these experiments. Different dilutions of each antibody were
incubated with the various pseudovirions prior to cell infection (see ‘Materials and methods’ for details); untreated pseudovirions (PSV) were used as a full infection (100%) control
in each assay.
353I. Rubio et al. / Virology 409 (2011) 348–359determinants of theHPV16-restricted binding/neutralization capacity of
mAb K8L228–42.
For the aa 72–78 L2 epitope bound by K1L264–81, the primary
HPV58 sequence differs at three positions from that of HPV16. While
the HPV16 peptide was recognized by mAb K1L264–81, the HPV58
peptide was not (Fig. 6B). An I→V substitution at position 73 of the
HPV58 peptide as well as a T→S substitution at position 77 only
partially restored K1L264–81 binding. By contrast, a full recovery ofD I I N K V E G K T
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Fig. 6. Reactivity of antibodies K8L228–42, and K1L264–81 with hybrid peptides derived from
mAbs K8L228–42 (aa 31–40; panel A) and K1L264–81 (aa 71–79; panel B) were used to inve
activity of these antibodies. The reactivities of each antibody with unmodiﬁed L2 peptides f
amino acid substitutions were determined by peptide ELISA (see ‘Materials and methods’ fK1L264–81 binding was obtained upon substitution of the Thr residue
at position 78 of HPV58 with an Arg residue as in HPV16.
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Fig. 7.Neutralization of HPV31 pseudovirions containing sequence-modiﬁed variants of
the L2 protein by antibodies K8L228–42, and K1L264–81. Pseudovirions bearing the
indicated HPV16-adapted variants of HPV31 L2 in combination with HPV31 L1 were
used to investigate the molecular bases of the type-restricted neutralizing activity of
mAbs K8L228–42 (A) and K1L264–81 (B). Single or multiple (2–4) amino acid
substitutions were inserted in the core peptide epitopes (aa 31–40 and 71–79)
recognized by the two antibodies. Unmodiﬁed HPV16 and HPV31 pseudovirions, mixed
pseudovirions containing HPV16L1/31 L2 and HPV31L1/16 L2 were used as controls.
The cross-neutralizing K18L220–38 and the K1L264–81 antibodies served as controls for
the experiment shown in Fig. 7A, and the K18L220–38 and the K8L228–42 were used as
controls for the experiment shown in Fig. 7B.
354 I. Rubio et al. / Virology 409 (2011) 348–359type-speciﬁcity of mAbs K1L264–81 and K8L228–42. To ﬁnd out whether
the L1 protein inﬂuences HPV16-restricted neutralization by these
antibodies, e.g. by imposing structural constraints on the L2 protein,
we studied the effect of L1 on K1L264–81- and K8L228–42-mediated
neutralization with the use of hybrid L1/L2 pseudovirions. In
particular, HPV16 L2 was analyzed in combination with HPV31 L1,
HPV18 L1 and HPV45 L1. In all cases, as long as HPV16 L2 was present,
equal levels of neutralization by K1L264–81 and K8L228–42 were
observed. Conversely, HPV31 L2 was studied in combination with
HPV16 L1. In this case, despite the presence of HPV16 L1,
neutralization by K1L264–81 and K8L228–42 was not observed, while all
pseudovirions were efﬁciently neutralized by the cross-neutralizing
antibody K18L220–38 (data not shown).
Neutralization of HPV31 pseudovirions bearing altered L2 epitopes by
K1L264–81 and K8L228–42
To identify key amino acid residues within the aa 32–39 and 72–78
L2 epitopes that are required for neutralization by the type-restricted
K8L228–42 and K1L264–81 antibodies, the corresponding regions of
HPV31 were chosen as models of an HPV type that cannot be
neutralized by such antibodies. For K8L228–42, the aa 31–40 region of
HPV31 L2 was mutagenized systematically in order to introduce
amino acid residues found in HPV16 (see Fig. 7A). The HPV31
pseudovirion construct comprising all four HPV16 L2 amino acid
substitutions (Ile 32, Val 36, Gly 38 and Lys 39) was efﬁciently
neutralized by K8L228–42 (Fig. 7A; for transducing activities of the
different pseudovirions see Supplementary Table 1). Pseudovirions
lacking either Val 36 or Lys 39 escaped neutralization, while Ile 32 and
Gly 38 did not appreciably inﬂuence neutralization efﬁciency. This
ﬁnding further conﬁrms the requirement of a lysine residue at
position 39 for neutralization, as observed in peptide ELISAs.
A similar strategy was applied to the aa 71–80 region of HPV31 L2
(Fig. 7B). In this sequence, three amino acids differ between HPV31
and HPV16 at positions 73, 76 and 80. Surprisingly, even modiﬁed
HPV31 pseudovirion constructs bearing all three HPV16 substitutions
failed to be neutralized by K1L264–81, as were constructs bearing only
single or double substitutions. Hybrid particles consisting of
HPV31L1/16 L2 were neutralized effectively by K1L264–81. Altered
pseudovirions and the HPV31L1/16 L2 showed comparable transduc-
ing activity in this assay (Supplementary Table 1). We then performed
a peptide ELISA in which HPV 31 L2 (aa 71–80) peptides bearing
single as well as double amino acid changes at positions 73, 76 and 80
were compared with the corresponding HPV16 peptide with respect
to K1L264–81 binding. As revealed by these assays (not shown), the
authentic HPV31 peptide was bound by K1L264–81, albeit to a lower
extent compared to the corresponding HPV16 peptide, and binding
was improved by introduction of a glycine at position 76 or a proline
at position 80. Taken together, these ﬁndings indicate that the HPV31
peptide is recognized, albeit rather weakly, by K1L264–81 and suggest
that the linear, aa 71–80 sequence of HPV31 L2 is not primarily
responsible for the lack of neutralization.
From neutralization assays using mixed (L1/L2) pseudovirions we
concluded that neutralization by K1L264–81 is not inﬂuenced by the L1
protein. To ﬁnd out whether L1 inﬂuences HPV type-speciﬁcity, we
investigated the combined effects of the L1 type and of the primary L2
epitope sequence on neutralization by this antibody. To this end, the
HPV31 L2 variant V73I, S76G, S80P was used in combination with
HPV16 L1 to assemble hybrid pseudovirions that were analyzed for
neutralization by K1L264–81. We found that despite the presence of
HPV 16 L1, K1L264–81 was not able to neutralize any of the
aforementioned hybrid pseudovirions, which were neutralized
instead by the positive control antibodies K18L220–38 and L1-
1.3.5.15 (data not shown). Thus, neither the L1 protein nor the
sequence of the aa 71–80 epitope embedded in a heterologous (HPV
31) L2 protein restrict neutralization by mAb K1L264–81 to HPV16.Discussion
This study focused on the ﬁne mapping of immune epitopes
within the N-terminus of the minor capsid protein L2, a promising
candidate for the development of novel broad range anti-HPV
vaccines. Forty-six monoclonal antibodies directed against regions
of the L2 protein potentially capable of eliciting virus neutralizing
immune responses were used as probes. From the reactivity patterns
of these mAbs we learned that all but four antibodies reacting with
different L2 epitopes are in fact non-neutralizing. This is quite
surprising, as each of the examined epitopes comprises only a short
region of the L2 protein. Although a particular subset of monoclonal
antibodies might not necessarily reﬂect total serum reactivity, the
data are in line with our previous ﬁnding that only a fraction of
antibodies directed against selected L2 epitopes are indeed neutral-
izing (Rubio et al., 2009). The observation that antibodies directed
against HPV16 L2 neutralizing epitopes can be either non-
355I. Rubio et al. / Virology 409 (2011) 348–359neutralizing, neutralizing but HPV16 type-restricted, or cross-
neutralizing, raises a question as to the determinants of these three
different immune responses. Failure to neutralize could be explained
by the inability of the antibodies to bind to the L2 target when
present in the context of virus particles. Alternatively, non-
neutralizing antibodies might be unable to interfere with key
infection processes such as virion uptake, transport or uncoating,
despite epitope binding. Further experiments aimed to analyze virus
neutralization mechanisms are under way. In particular, it will be
interesting to determine whether non-neutralizing antibodies are
able to compete with neutralizing antibodies directed against the
same region of L2. It will also be interesting to ﬁnd out whether some
non-neutralizing epitopes can act as decoys for the neutralizing ones.
Another important issue is what distinguishes antibodies only
capable of neutralizing HPV16 from broadly cross-neutralizing
antibodies. The simplest possibility would be that type-restricted
antibodies fail to neutralize different HPV types because of their
inability to react with different variants of the same L2 target
sequence. It is equally conceivable, however, that not the L2 protein
itself, but rather the structural constraints imposed by the L1 scaffold
are limiting access of certain types of antibodies to their target
antigens. In the case of HPV31 pseudovirions, which partially (or
totally) escaped neutralization by two otherwise cross-neutralizing
antibodies, the data obtained with hybrid pseudovirions indicate that
escape is not due to the L1 protein, but rather to subtle sequence
differences between the HPV31 and HPV16 L2 proteins. These results,
however, also indicate that at least the N-terminal portion of the L2
proteins from different HPV types can adopt a very similar structural
organization within viral capsids.
The mechanisms of L2-directed neutralization are not yet fully
understood.
For mAb RG1 it has been proposed that exposure of the aa 17–36
epitope in HPV16 only occurs after (pseudo) virion binding to the cell
surface and L2 cleavage by the cellular furin protease (Day et al.,
2008a,b; Richards et al., 2006). In the presence of RG1 virions are
released from the cells and reattach to the extracellular matrix
because the antibody prevents interaction with a secondary receptor
(Day et al., 2008a,b). The two cross-neutralizing antibodies charac-
terized in this study (K4L220–38 and K18L220–38) both overlap the RG1
epitope and require the two cysteine residues present in this region
(C22 and C28) for binding. These cysteines are conserved among
different papillomaviruses and have recently been shown to be
disulﬁde-bonded in infectious virus particles (Campos and Ozbun,
2009). The latter ﬁnding is in line with our observation that both
mAbs (K4L220–38 and K18L220–38) have a strong preference for the
oxidized (S–S) rather than the reduced (SH) form of the aa 20–38 L2
peptide. As suggested by the behaviour of mAb K15L220–38, which
shares a recognition pattern very similar to that of K4L220–38 and
K18L220–38, yet failed to neutralize, binding afﬁnity represents
another important requirement for neutralization. In addition, eight
antibodies recognize the C-terminal portion of the RG1 epitope (aa
27–35), yet lack neutralizing activity. This suggests that this region
may remain inaccessible even after furin cleavage. It should be noted,
however, that a sequence immediately downstream to the epitope
recognized by these non-neutralizing mAbs has been shown to
interact with syntaxin 18, albeit at a later stage of the infection cycle
(Bossis et al., 2005). In fact, we found another neutralizing antibody
(K8L228–42) which binds to an epitope located just upstream of the
putative syntaxin 18 interaction site. This is consistent with results
showing that residues 36–49 of BPV 1 also become exposed during
virus entry (Laniosz et al., 2007). In contrast to K4L220–38 and
K18L220–38, the K8L228–42 antibody speciﬁcally neutralizes HPV16
pseudovirions only. Therefore the aa 21–39 region of L2, which
includes the most upstream portion of the epitope recognized by the
RG1 mAb, contains the target epitopes for two different types of
neutralizing antibodies (HPV16-restricted and cross-neutralizing),separated by a short stretch of amino acids recognized by non-
neutralizing antibodies.
We isolated monoclonal antibodies targeting three other regions
of L2 (aa 56–75; aa 64–81; aa 96–115). Although the sera of mice from
which these antibodies were derived were all able to neutralize
HPV16 pseudovirions, only one of the corresponding mAbs, directed
against the aa 64–81 region, was endowed with neutralizing activity.
The epitope recognized by this mAb overlaps the binding site of a
previously isolated anti-HPV16 neutralizing antibody (mAb6; Kawana
et al., 1999). Virus neutralizationmechanisms based on binding to this
particular region of L2 have not been described yet and it remains to
be determined at what stage in the infection cycle this epitope
becomes exposed.
Two of the four neutralizing antibodies (K8L228–42 and K1L264–81)
failed to neutralize papillomavirus types other than HPV16. This lack
of cross-neutralization can be ascribed to the relatively poor amino
acid sequence conservation of the corresponding epitopes (see Fig. 8).
In fact, binding of K8L228–42 to the HPV52/58 aa 31–40 peptide could
be restored by replacing Thr39 with a lysine, the amino acid residue
present at this position in HPV16 L2. The same T39K replacement,
together with two additional amino acid substitutions, allowed for
neutralization of hybrid pseudovirions bearing HPV16-adapted
variants of HPV31 L2 by K8L228–42. This resembles the behaviour of
the epitope recognized by K4L220–38 and K18L220–38, where single
amino acid substitutions reduced (or abolished) neutralization of
HPV31 compared to HPV16 pseudovirions. Although monoclonal
antibodies represent a somewhat artiﬁcial situation, our ﬁndings raise
a question as to whether there are natural escape mechanisms for L2-
directed neutralizing antibodies analogous to the hypervariable loops
present in L1 VLPs. Unfortunately, there is no information on naturally
occurring anti-L2 neutralizing antibodies, and by using hybrid
particles we only detected neutralizing activity directed against the
L1 protein in a screening conducted on 10 human sera (M.M.,
unpublished observations).
At variance with the other three epitopes recognized by neutral-
izing antibodies, type-restricted neutralization of HPV16 pseudovir-
ions by K1L264–81 was not affected by the introduction of HPV16-
speciﬁc amino acids in the heterologous L2 protein from HPV31 (aa
71–80), despite improved binding of the K1L264–81 mAb to the
corresponding isolated peptides. This indicates the involvement of
higher-order constraints in the recognition of, and neutralization
mediated by, this particular epitope. One possibility is that this
epitope has an intrinsically reduced accessibility within a HPV31 L1/
L2 particle. Alternatively, HPV31 L2 might allow for alternative virus
entry pathways, which are not blocked by antibody binding. In either
case, a vaccination approach relying on this particular HPV31 L2
peptide as antigen is expected not to elicit a neutralizing immune
response.
Because of its ability to induce broadly protective antibody
responses, the L2 protein is an attractive candidate for the
development of a novel prophylactic anti-HPV vaccine. Several
attempts have been made to increase the immunogenicity of L2
(Alphs et al., 2008; Rubio et al., 2009; Schellenbacher et al., 2009;
Slupetzky et al., 2007). Our data indicates that the immunogenicity of
the L2 N-terminus is not so poor per se, but that only a minor fraction
of the immune responses induced by peptide epitopes from this
region leads to effective neutralization. This is in stark contrast to VLP-
based vaccines, where antibodies directed against intact viral capsids
are almost always neutralizing. Therefore, in the case of L2 the
challenge is to re-direct the B-cell response so to produce mainly
cross-neutralizing antibodies with a reactivity pattern similar to that
of mAb K18L220–38.
What deﬁnes a cross-neutralizing L2 epitope? As suggested by this
study, the most important requirements are a strong sequence
conservation, a high accessibility, and spatial proximity to functionally
critical regions of L2, antibody binding to which hinders interaction
Fig. 8. Positional conservation proﬁle of N-terminal HPV L2 polypeptides. Aligned N-terminal (aa 1–120) L2 polypeptide sequences from 21 HPV serotypes were analyzed for
sequence conservation (see ‘Materials and methods’ for details). Numbers on the x-axis are referred to the HPV16 L2 sequence and indicate the mid-point position of the sliding
window utilized for analysis (7 amino acids, moved by incremental steps of 1 residue positions). For each window position, average pairwise percent identity values derived from
multiple sequence alignment are represented as histogram bars. The reference sequence shown below the graph is from HPV16 L2. Also shown are the epitopes recognized by the
four neutralizing antibodies identiﬁed in this study as well as the binding sites of previously characterized neutralizing mAbs (MAb6 and MAb5/13, Kawana et al, 1999; RG1,
Gambhira et al., 2007b), and various functional regions potentially involved in HPV internalization.
356 I. Rubio et al. / Virology 409 (2011) 348–359with cellular components involved in virus internalization. The aa 20–
31 epitope seems to fulﬁll the aforementioned criteria, as it is the
second best conserved sequence element within the L2 N-terminus,
and by being located between the furin cleavage site and the syntaxin
18 binding site it likely overlaps the putative L2 receptor (see Fig. 8).
So far, all attempts to induce anti-L2 neutralizing antibody
responses have targeted linear L2 epitopes. The reason for this has
to do with the inability to present L2 to the immune system in the
context of L1 VLPs providing for an authentic L2 conformation.
Notably, anti-L1 neutralizing antibodies are almost exclusively
directed against conformational epitopes.
Besides important insights on the molecular bases of L2-mediated
cross-protective immunity and new antibody reagents for studying the
HPV infection cycle, the results of the present high resolution analysis
provide a useful framework for the development of novel L2-based
vaccines. The anticipatedmajor challenge will be to effectively re-direct
the immune response from irrelevant epitopes to functionally important
sites of the L2 protein.
Materials and methods
Isolation of monoclonal antibodies
HPV type 16 L2 peptides covering aa regions 20–38, 28–42, 56–75,
64–81, 96–115 and 1–120 were internally fused to bacterial
thioredoxin as described before and used to vaccinate 6–8 month-
old female Balb/c mice (Charles River Laboratories; Sulzfeld,
Germany) (Rubio et al, 2009). After analysis of immune sera by
GST-L2 ELISA and neutralization assays, mice with the strongest
serum reactivities were selected for mAb production. Brieﬂy,
splenocytes were fused with SP2/0 myeloma cells and maintained
in selection medium containing Hypoxanthine Aminopterin Thymi-
dine (HAT) supplemented with Hybridoma Fusion and Cloning
Supplement (HFCS; Roche). Positive clones, selected by GST-L2
ELISA, were sub-cloned four times and the immune reactivity of thecorresponding hybridoma supernatants was evaluated by immuno-
ﬂuorescence (IF), immunoblot (IB) and the ability to neutralize PV
pseudovirions.
Detection of anti-HPV16 L2 antibodies
GST-capture ELISA was used for the detection of HPV16 L2
antibodies. To this end, microtiter plates were coated overnight at
4 °C with 50 μl of coating buffer containing glutathione-casein,
blocked with 0.2% casein in PBS, pre-warmed at 37 °C, followed by
the addition of 50 μl of GST-L2 (aa 1–120) and incubation for 1 h at
37 °C (Sehr et al., 2001). Plates were washed with PBS-0.3% Tween 20
prior to the addition of 50 μl aliquots of hybridoma supernatants and
incubation for 1 h at 37 °C. Plates were then washed again and
incubated for 1 h at 37 °C with 50 μl/well of a horseradish peroxidase
(HRP)-conjugated goat anti-mouse IgG polyclonal antibody (Sigma-
Aldrich) diluted 1:3000 in PBS-0.3% Tween 20 plus 0.2% casein. After a
further washing with PBS-Tween 20, 100 μl of 2,2′-azino-bis(3-
ethylbenz-thiazoline-6-sulfonic acid) (ABTS; 1 mg/ml in 100 mM
sodium acetate-phosphate buffer, pH 4.2, containing 0.015% H2O2)
were added to each well and absorbance at 405 nm was measured
after 10–20 min with an automated plate reader (Titertek).
Immunoglobulin isotype identiﬁcation
Monoclonal antibody producing cell lines were isotyped using a
Hybridoma Sub-isotyping Kit (Calbiochem Novagen). Brieﬂy, 96-well
plates were coated with 100 μl of goat anti-mouse IgG diluted 1:1000
in coating buffer. Plates were incubated overnight at 4 °C and, after
washing three times with PBS-0.1% Tween 20, were blocked with
200 μl of blocking serum diluted 1:4 in PBS-0.1% Tween 20 and
incubated at room temperature (RT) for 1 h. Fifty μl of hybridoma
supernatants were added to each well and incubated at RT for 1 h.
Individual supernatants were tested with 100 μl of rabbit anti-IgM,
anti-IgG1, anti-IgG2a, anti-IgG2b, anti-IgG3 and anti-IgGA, using PBS
357I. Rubio et al. / Virology 409 (2011) 348–359as a negative control. Following incubation for 1 h at RT, reactions
were developed by adding 100 μl of HRP-conjugated sheep anti-rabbit
IgG polyclonal antibody (Sigma-Aldrich) diluted 1:3000 with PBS-
0.1% Tween 20 in blocking serum. After a further washing with PBS-
Tween 20, plates were stained as described earlier.
Indirect immunoﬂuorescence
1.5×105 293TT cells/ml were seeded in 12-well plates with glass
cover slides for 24 h before transfection with a plasmid encoding
HPV16 L2. Cells were washed twice with PBS and ﬁxed with 1 ml of
absolute ethanol at−20 °C for 10 min; cells were then re-hydrated by
washing twice with PBS and blocked with a solution of 5% PBS-milk
overnight at 4 °C. Wells were incubated with hybridoma supernatants
for 1 h at RT and washed three times with PBS. After washing, wells
were incubated for 1 h at RT in the darkness with ﬂuorochrome-
conjugated anti-mouse rabbit antibody diluted 1:400. Glasses were
washed three times with PBS-0.3% Tween 20, embedded in Fluoprep
(BioMérieux) and analyzed with a Leica-DMRD microscope.
Immunoblotting
293TT cells transfected as described earlier for immunoﬂuores-
cence were washed with PBS, collected in 200 μl of PBS-lysis buffer
containing SDS and β-mercaptoethanol, and boiled at 100 °C for
10 min. Samples were fractionated on 12.5% SDS-polyacrylamide gels
and blotted onto nitrocellulose membranes, which were blocked
overnight at 4 °C in PBS–0.1% Tween 20 containing 5% skim milk
powder (blocking solution) and incubated for 1 h at RT with mAb-
containing supernatants. Membranes were washed three times with
PBS–0.3% Tween 20 for 5 min and then incubated with a HRP-
conjugated goat anti-mouse IgG polyclonal antibody (Sigma-Aldrich)
diluted 1:3000 in PBS-0.3% Tween 20 plus 5% milk for 1 h at RT. After
washing, the L2 protein was detected with an enhanced chemilumi-
nescence detection kit (Applichem).
A similar immunoblotting procedure was used to determine the
immune reactivity of mAbs K18L220–38 and K4L220–38 with the
oxidized (S–S) and the reduced (SH) form of the TrxL2(20–38)3
antigen. As revealed by 5,5′-dithio-bis(2-nitrobenzoic) acid (DTNB)
analysis using N-acetyl cysteine as standard, N97% of the 8 SH groups/
molecule harboured by TrxL2(20–38)3 are in a disulﬁde-bonded form
in the recombinant polypeptide puriﬁed from bacterial lysates. A
reduced form of the polypeptide, bearing on average 6±1 DTNB-
reactive SH groups/molecule, was prepared by treatment of TrxL2
(20–38)3 (1 mg/ml) with 0.3 M β-mercaptoethanol at 25 °C for
30 min and checked by DTNB analysis after removal of excess β-
mercaptoethanol on size-exclusion spin columns (Micro BioSpin 6,
BioRad).
IgG quantiﬁcation
Antibody concentrations in the supernatants of hybridoma cells
were determined by ELISA. 96 well plates (BD-Falcon) were incubated
overnight at 4 °C with 50 μl of sheep anti-mouse antibody IgG diluted
in PBS (1.6 μg/μl). Plates were washed three times with PBS-0.3%
Tween 20 and blocked with 3% milk in PBS for 1 h at 37 °C. Ten serial
dilutions of a commercial mouse IgG (1 mg/ml), starting from 1:1000,
were used as standards. Fifty μl of calibrators and supernatants diluted
1:100, 1:200 and 1:400was seeded in thewells and incubated at 37 °C
for 1 h. After three more washings with PBS-0.3% Tween 20, plates
were incubated with 50 μl of HRP-conjugated goat anti-mouse IgG
polyclonal antibody diluted 1:3000 in PBS-0.3% Tween 20 plus 3%
milk. Following a further washing with PBS-Tween 20 plates were
stained as described earlier. Calibration curves were used to calculate
IgG concentration.Biacore analysis
Surface plasmon resonance (SPR)measurementswere performed on
a Biacore T100 machine equipped with CM5 sensor chips (Biacore,
Uppsala, Sweden)using10mMHepespH7.4, 150mMNaCl, 3mMEDTA,
0.05% Tween20 and 1mM DTT as running buffer at 25°C. Polyclonal
immunosorbent puriﬁed rabbit anti-mouse Ig (Biacore, BR-1005-14)
was immobilized to the sensor surface of two ﬂow cells using standard
amine-coupling chemistry according to the manufacturers’ instruction.
Monoclonal antibodies (K4L220-38, K18L220-38, and K15L220-38) were
consecutively captured from undiluted hybridoma supernatants to one
ﬂow cell, the other ﬂow cell coated with capture antibody served as
reference. Twofold serial dilutions of Trx-L2 (1-120) ranging from
0.98-1000 nM were injected over the captured mAb and reference
surface. Regeneration of the capture surface between different mAbs
(supernatants)was donewith 10mMglycine pH 2.0 at a ﬂow rate of 30
µl/min for 30 s. Sensorgrams were processed using double referencing
and the equilibrium dissociation constants were determined by steady
state afﬁnity evaluation with the Biacore T100 Evaluation Software.
Pseudovirion preparation
Pseudovirions were prepared as previously described (Buck et al.,
2005) by co-transfection of the 293TT cell line derived by transfor-
mation of human embryonic kidney cells, with a plasmid bearing the
humanized HPV16 L1 and L2 genes along with an SV40 replication
origin (pCDNA4-HPV16L1h-L2h/SV40ori) and a second plasmid
harbouring the reporter enzyme “secreted form of placental alkaline
phosphatase” (SEAP) under the control of the CMV promoter
(pCMVSEAP). Co-transfection was routinely performed on 7×106
293TT cells previously seeded on 10 cm culture dishes in Dulbecco
modiﬁed Eagle'smedium(DMEM; Sigma-Aldrich) supplementedwith
10% fetal calf serum (FCS; Gibco-BRL), 1% penicillin/streptomycin (Life
Technologies), and 125 μg/ml hygromycin (Roche), using TurboFect
(Fermentas) according to the manufacturer's instructions with minor
modiﬁcations. Brieﬂy, 8 μg of each plasmid was mixed with 80 μl of
PolyFectR in 800 μl of culturemedium, incubated for 10 min and added
to the cells, which were then incubated at 37 °C for 3–4 days. For
pseudovirion extraction, 5×107 cells were harvested by trypsiniza-
tion,washedoncewith PBS, and resuspended in 1 ml of PBS containing
1 mM CaCl2 and 5.6 mMMgCl2. After the addition of 4 μl of benzonase
(250 U/ml; Sigma-Aldrich) and 50 μl of Brij 58, cells were incubated at
37 °C overnight to induce pseudovirion maturation. They were then
supplemented with NaCl to a ﬁnal concentration of 710 mM, followed
by a 10 min incubation at 4 °C. The resulting lysate was cleared by
centrifugation (10 min at 3500×g), pseudovirions were collected,
divided in aliquots and immediately stored at−70 °C.
Neutralization assays
Prior to infection, 293TT target cellswere seeded for 24 h at a density
of 15,000 cells per well in 96-well plates ﬁlled with DMEM supple-
mented with 10% FCS, 1% penicillin/streptomycin and 125 μg/ml
hygromycin. The following day, pseudovirions were diluted in DMEM
dependingon their transducing activity to obtain a value between 2 104
and 3 105 relative units of luminiscense (RUL) andmixedwith different
dilutions of the anti-L2 antibodies. After 15 min at room temperature,
the culture medium was replaced with 200 μl of the aforementioned
pseudovirion solution. SEAP activity in cell culture supernatants was
determined ﬁve days post-infection using the chemiluminescent SEAP
Reporter Gene Assay (Roche) as per manufacturer's instructions. All
anti-L2mAbswere tested induplicate. In eachneutralization (andcross-
neutralization) assay, the following controls were included: untreated
cells, cells treated with the pseudovirions alone (i.e., without any added
antiserum), cells treatedwith pseudovirions preincubated (as described
for Trx-L2 peptide antisera; Rubio et al., 2009) with established
358 I. Rubio et al. / Virology 409 (2011) 348–359neutralizing mAbs speciﬁc for HPV31 (H31.A6 diluted 1:1000;
(Christensen et al., 2001, 1996)), HPV45 (H45.L10 diluted 1:1000;
(Combita et al., 2002)) and HPV16 (Ritti01 diluted 1:1000; (Rizk
et al., 2008)), or with polyclonal antibodies against HPV18 (rat #2;
diluted 1:2000) and HPV58 (human 109; diluted 1:1000) as required
by each neutralization experiment.
Peptides
Biotinylated 15-mer peptides covering the N-terminal 120 aa of L2
with an offset of 4 amino acids each were produced by chemical
synthesis. Other peptides covering the aa 20–38 region were
generated by stepwise (one amino acid) shortening from the N- and
the C-terminus until an 8-mer peptide size was reached. For alanine-
scanning, variants of the aa 20–31 region of HPV16 L2 were produced
by replacing each amino acid residue with alanine. All peptides were
synthesized byMimotopes (Australia). Biotinylated peptides covering
the aa 20–31 regions of HPV31 and HPV16 L2 as well as variant
peptides with amino acid residues of the original HPV16 sequence
replaced by glycine residues were synthesized at the DKFZ core
facility.
Peptide ELISA
Supernatants were tested for peptide binding using biotinylated
peptides. Microtiter plates were coated with 50 μl of streptavidin
(Sigma S4762; 1 mg/ml) diluted 1:400 with distilled water. Plates
were incubated overnight at 37 °C; blocked with PBS-Casein 0.2% and
further incubated for 1 h at RT. After each step plates were washed
three times with PBS-0.3% Tween 20. Peptides previously resus-
pended in 50% acetonitrile and 5% acetic acid (or DMSO) were diluted
to a concentration of 1 μg/μl in PBS; 50 μl of each peptide dilutionwere
then added to the wells and incubated for 1 h at RT. Fifty μl of each
supernatant diluted 1:10 were added to ELISA plates and incubated
for 1 h at RT. Plates were then washed, incubated for 1 h at RT with
50 μl/well of a HRP-conjugated goat anti-mouse IgG polyclonal
antibody (Sigma-Aldrich) diluted 1:3000 in PBS-0.3% Tween 20 plus
0.2% casein, and stained as described earlier.
Site-directed mutagenesis
Threemutations were introduced into the HPV 31 L2 gene (at once
or stepwise) in order to adapt the HPV31 L2 sequence at speciﬁc
positions to that of HPV16; themutated genes are referred to as Q20K,
A24K and S30P. Mutants were generated with the Quick Change
Mutagenesis Kit (Stratagene). Four additional mutations (referred to
as V32I, I36V, H38G and T39K) were introduced (at once or stepwise)
in the aa 31–40 epitope and three mutations (V73I, S76G and S80P) in
the aa 71–80 epitope of the HPV31 L2 gene in order to revert the
HPV31 sequence to that of HPV16 at these positions; these mutants
were generated with the QuikChange II-E and QuikChange II-XL Site-
Directed Mutagenesis Kits (Stratagene) (oligonucleotide sequences
are available on request).
Sequence analysis
N-terminal (aa 1–120) L2 sequences from 21 HPV serotypes were
retrieved from GenBank (NP_040308.1, AAY86489.1, AAY86491.1,
P06419.1, AAF00067.1, ACL12349.1, AAD33258.1, ABP99806.1,
AAY86493.1, AAA46955.1, ACL12332.1, CAA52589.1, ACL12324.1,
AAA46971.1, ACL12340.1, ABO76829.1, AAA47055.1, P26539.1, gb|
ACL12357.1, CAA63886.1, BAA90741.1), aligned with ClustalW, and
percent identity values were calculated using the AlgnIO module of
Bio-Pearl. Average pairwise percent identities were determined using
sliding windows of 7 amino acids with an incremental step of 1
residue positions.Supplementarymaterials related to this article can be found online
at doi:10.1016/j.virol.2010.10.017.
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